These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35833753)

  • 21. A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities.
    Zhou H; Chen C; Sun L; Zeng Z
    Contemp Clin Trials; 2021 Jun; 105():106404. PubMed ID: 33862287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Keyboard design for phase I drug-combination trials.
    Pan H; Lin R; Zhou Y; Yuan Y
    Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
    Guo W; Wang SJ; Yang S; Lynn H; Ji Y
    Contemp Clin Trials; 2017 Jul; 58():23-33. PubMed ID: 28458054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the effects of design parameters on the performances of phase I trial designs.
    Zhu Y; Hwang WT; Li Y
    Contemp Clin Trials Commun; 2019 Sep; 15():100379. PubMed ID: 31193764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian optimal interval design with multiple toxicity constraints.
    Lin R
    Biometrics; 2018 Dec; 74(4):1320-1330. PubMed ID: 29870069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries.
    Li C; Pan H
    PLoS One; 2020; 15(8):e0237254. PubMed ID: 32853204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
    Chen X; Zhang J; Jiang Q; Yan F
    J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving early phase oncology clinical trial design: A case study.
    Phillips AJ; Clark TP
    Pharm Stat; 2022 Nov; 21(6):1370-1375. PubMed ID: 35765820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of the BOIN design and its current extensions for novel early-phase oncology trials.
    Ananthakrishnan R; Lin R; He C; Chen Y; Li D; LaValley M
    Contemp Clin Trials Commun; 2022 Aug; 28():100943. PubMed ID: 35812822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Bayesian design for finding optimal biological dose with mixed types of responses of toxicity and efficacy.
    Zhang D; Xu J
    Contemp Clin Trials; 2023 Apr; 127():107113. PubMed ID: 36758934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approximate Bayesian computation design for phase I clinical trials.
    Jin H; Du W; Yin G
    Stat Methods Med Res; 2022 Dec; 31(12):2310-2322. PubMed ID: 36031856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
    Takeda K; Xia Q; Liu S; Rong A
    Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.
    Cunanan K; Koopmeiners JS
    BMC Med Res Methodol; 2014 Apr; 14():51. PubMed ID: 24731155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials.
    Zhou Y; Lin R; Kuo YW; Lee JJ; Yuan Y
    JCO Clin Cancer Inform; 2021 Jan; 5():91-101. PubMed ID: 33439726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials.
    Mu R; Xu G; Liu G; Pan H
    Contemp Clin Trials; 2021 Sep; 108():106504. PubMed ID: 34303862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials.
    Park M; Liu S; Yap TA; Yuan Y
    JAMA Netw Open; 2021 Feb; 4(2):e2037563. PubMed ID: 33595664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian optimal interval design for dose finding in drug-combination trials.
    Lin R; Yin G
    Stat Methods Med Res; 2017 Oct; 26(5):2155-2167. PubMed ID: 26178591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
    Lin R; Yin G
    Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced cumulative sum charts for monitoring process dispersion.
    Abujiya MR; Riaz M; Lee MH
    PLoS One; 2015; 10(4):e0124520. PubMed ID: 25901356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.